Texas Gov. Greg Abbott asked the federal government for $11 billion as a reimbursement for the border security measures he ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

In my last column about the Novo Nordisk Foundation, I wrote about the company’s efforts in anti-microbial resistance, an example of an area where impact investment was necessary to combat ...

This article introduces the largest foundations in the world, fostering changes and improvements across various sectors to create a better world.

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Find insight on Novo Nordisk Foundation, ResMed, Johnson & Johnson, and more in the latest Market Talks covering Health Care.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.